Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference PR Newswire JERSEY CITY, N.J., Dec. 5, 2012 JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ --Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23^rd Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at 2:45 PM Eastern Time in New York and provide a business overview and update. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.Replays of the presentation will be available at the same location for 30 days following the conference. AboutOptimer Pharmaceuticals Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, anFDA-approved macrolide antibacterial drug for the treatment ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in theEuropean Unionwhere its partner,Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The Company is exploring marketing authorization in other parts of the world whereC. difficilehas emerged as a serious health problem, includingAsia. Additional information can be found at http://www.optimerpharma.com. Contacts Optimer Pharmaceuticals, Inc. David Walsey, VP of Investor Relations and Corporate Communications (858) 964-3418 Canale Communications Jason I. Spark, Senior Vice President (619) 849-6005 SOURCE Optimer Pharmaceuticals, Inc. Website: http://www.optimerpharma.com
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.